Hero Image


We’re at the forefront of research, seeking to translate scientific discoveries into treatments for people with immune-mediated inflammatory disorders.


Find a clinical trial

Research | Our focus | Careers I Collaborations

Our immunology research efforts

We have a proud legacy of developing novel therapeutics for people with immune-mediated inflammatory diseases and autoimmune-related disorders. Our deep knowledge of immuno-oncology and vaccines has laid the foundation for our scientists who are focused on drug discovery and development efforts for immune disorders.

Exploring new modalities

With an advanced understanding of human biology, there's been an emergence of innovative medicines and new modalities that aim to change the way we approach treatment for immune disorders. We’re investigating targets that have been implicated in many autoimmune-related diseases, including tumor necrosis factor-like ligand 1A (TL1A), interleukin-2 (IL-2) protein and CD30L.

scientist working in a lab
Bringing precision medicine to immunology

We’ve made significant investments over the past few years and hope to usher in a new era in immunology. We're pursuing biomarkers that could play a key role in identifying people who are more likely to respond to therapies. The ultimate goal is to be able to deliver the right medicine for the right patient at the right time.

Our focus on immunology research & treatments

It’s estimated as many as one in 10 people are living with immune disorders around the world.  We’re accelerating our growing capabilities in immunology and evaluating new treatment options for people with certain immune disorders.

Scientist smiling wearing goggles

Careers at Merck

Motivated to advance new research in immunology, we rely on world-class expertise. Our team is always growing, so join us and start making your impact today.

Business development & licensing

We follow the science where we can make the greatest difference, now and in the future. We’ve made significant investments over the past few years in immunology through business development and licensing opportunities.

Learn more

Following our acquisition of Prometheus Biosciences, we hope to usher in a new era of care for immune disorders based on a precision medicine approach.

As part of our acquisition of Pandion Therapeutics, we're evaluating novel therapeutics designed to address the unmet needs of people living with autoimmune-related diseases.

We've entered into a strategic research collaboration with Culmination Bio to access both clinical and paired specimen (tissue and blood) data in an effort to identify patient cohorts in immunology.

Explore more